LUCD

+ Watchlist + Portfolio

Lucid Diagnostics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.01
52-Week Range: $0.86 – $1.63
Market Cap: $183.39M
P/E (TTM): —
EPS (TTM): -0.41
Dividend Yield: —

Advanced Metrics

Price/Book: 16.85
PEG Ratio: —
Return on Equity: -556.27%
Return on Assets: -81.63%
Gross Margin: -21.69%
Operating Margin: -868.45%
Profit Margin: 0.00%
Current Ratio: 1.33
Debt/Equity: 2.28
Total Debt: $24.91M
Free Cash Flow: $-26.43M
Revenue Growth: 26.70%
Earnings Growth: —
Enterprise Value: $173.75M

LUCD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$377.00K	$2.43M	$4.35M	$4.71M
Cost of Revenue	$3.61M	$5.98M	$7.10M	$6.67M
Gross Profit	-$3.24M	-$3.55M	-$2.75M	-$1.96M
Research & Development	$11.26M	$7.25M	$5.99M	$5.68M
Selling, General & Admin	$40.11M	$35.66M	$36.62M	$41.58M
Operating Expenses	$53.01M	$44.93M	$43.30M	$47.68M
Operating Income	-$56.25M	-$48.48M	-$46.05M	-$49.64M
EBITDA	-$54.23M	-$49.75M	-$44.34M	-$57.12M
Pretax Income	-$56.17M	-$52.67M	-$45.53M	-$58.01M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$56.17M	-$52.67M	-$45.53M	-$58.01M
Diluted EPS	-1.55	-1.26	-1.05	-0.43
Diluted Shares	36.17M	41.76M	50.50M	164.11M

LUCD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$22.47M	$18.90M	$22.36M	$34.70M
Receivables	$17.00K	$45.00K	$405.00K	$643.00K
Inventory	$111.00K	$278.00K	$341.00K	$353.00K
Current Assets	$24.36M	$22.07M	$25.15M	$37.47M
Total Assets	$32.51M	$27.27M	$30.71M	$40.45M
Current Liabilities	$8.43M	$29.38M	$23.52M	$28.58M
Total Debt	$2.00M	$15.26M	$21.25M	$25.82M
Total Liabilities	$9.46M	$29.58M	$25.32M	$29.51M
Retained Earnings	-$98.08M	-$150.74M	-$203.77M	-$274.33M
Shareholders' Equity	$23.05M	-$2.31M	$5.39M	$10.94M
Working Capital	$15.93M	-$7.31M	$1.62M	$8.89M

LUCD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$29.68M	-$32.82M	-$44.14M	-$46.48M
Capital Expenditure	-$908.00K	-$221.00K	-$646.00K	-$197.00K
Free Cash Flow	-$30.59M	-$33.04M	-$44.79M	-$46.68M
Depreciation & Amortisation	$1.94M	$2.50M	$1.17M	$872.00K
Stock-Based Compensation	$14.99M	$6.82M	$4.53M	$4.49M
Investing Cash Flow	-$4.11M	-$221.00K	-$646.00K	-$197.00K
Financing Cash Flow	$2.61M	$29.46M	$48.25M	$59.03M
Net Change in Cash	-$31.18M	-$3.58M	$3.46M	$12.35M

LUCD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$828.00K	$1.16M	$1.21M	$1.50M	$1.26M
Cost of Revenue	$1.55M	$1.56M	$1.70M	$1.86M	$1.63M
Gross Profit	-$723.00K	-$400.00K	-$486.00K	-$356.00K	-$369.00K
Research & Development	$1.43M	$1.25M	$1.27M	$1.72M	$1.21M
Selling, General & Admin	$10.23M	$9.62M	$9.90M	$11.83M	$10.43M
Operating Expenses	$11.76M	$10.98M	$11.27M	$13.65M	$11.74M
Operating Income	-$12.49M	-$11.38M	-$11.76M	-$14.01M	-$12.11M
EBITDA	-$26.68M	-$4.21M	-$10.18M	-$16.05M	-$13.68M
Pretax Income	-$26.91M	-$4.44M	-$10.40M	-$16.27M	-$13.91M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$26.91M	-$4.44M	-$10.40M	-$16.27M	-$13.91M
Diluted EPS	-0.52	-0.08	-0.10	-0.10	-0.17
Diluted Shares	68.80M	98.99M	108.18M	162.66M	140.10M

LUCD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$25.24M	$31.12M	$47.33M	$34.70M	$27.88M
Receivables	$61.00K	$373.00K	$550.00K	$643.00K	$689.00K
Inventory	$484.00K	$505.00K	$486.00K	$353.00K	$469.00K
Current Assets	$27.54M	$33.83M	$49.84M	$37.47M	$31.36M
Total Assets	$32.80M	$38.67M	$53.20M	$40.45M	$34.08M
Current Liabilities	$36.57M	$29.43M	$26.21M	$28.58M	$29.39M
Total Debt	$35.27M	$27.55M	$24.34M	$25.82M	$26.80M
Total Liabilities	$38.17M	$30.81M	$27.36M	$29.51M	$30.08M
Retained Earnings	-$239.78M	-$247.67M	-$258.07M	-$274.33M	-$297.96M
Shareholders' Equity	-$5.38M	$7.86M	$25.84M	$10.94M	$4.00M
Working Capital	-$9.03M	$4.41M	$23.64M	$8.89M	$1.98M
Net Debt	$7.56M	—	—	—	—

LUCD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$12.46M	-$10.55M	-$10.89M	-$12.58M	-$12.10M
Capital Expenditure	-$93.00K	-$25.00K	-$28.00K	-$51.00K	-$215.00K
Free Cash Flow	-$12.56M	-$10.57M	-$10.92M	-$12.63M	-$12.32M
Depreciation & Amortisation	$221.00K	$222.00K	$220.00K	$209.00K	$222.00K
Stock-Based Compensation	$1.03M	$1.14M	$1.15M	$1.17M	$1.41M
Investing Cash Flow	-$93.00K	-$25.00K	-$28.00K	-$51.00K	-$215.00K
Financing Cash Flow	$15.44M	$16.46M	$27.13M	$2.00K	$5.49M
Share Repurchases	$0.00	—	—	—	-$17.00K
Net Change in Cash	$2.88M	$5.88M	$16.21M	-$12.63M	-$6.83M

Market Snapshot

About

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on esophageal cancer detection. The company develops non-invasive tests for early detection of esophageal precancer and cancer, including the EsoGuard test. Their technology aims to improve patient outcomes through earlier diagnosis of esophageal adenocarcinoma and its precursor condition, Barrett's esophagus.